Since TP53 missense mutations encode mutant p53 proteins that have one amino acid different from wild-type p53, scientists have long considered whether these proteins can be presented by tumor cells or antigen-presenting cells, and can be a target for immunotherapy. Here, TP53 is linked to neoplasm.